About Day One
Day One is a company based in San Francisco (United States) founded in 2018 by Sam Blackman was acquired by Servier in March 2026. It operates as a Direct-to-Consumer (D2C). Day One has raised $190 million across 2 funding rounds from investors including T. Rowe Price, Franklin Templeton and Janus Henderson Investors. The company has 181 employees as of December 31, 2024. Day One has completed 1 acquisition, including Mersana. Day One offers products and services including OJEMDA™ (tovorafenib) and Tovorafenib DAY301.
- Headquarter San Francisco, United States
- Employees 181 as on 31 Dec, 2024
- Founders Sam Blackman
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Day One Biopharmaceuticals, Inc.
-
Annual Revenue
$131.16 M (USD)0as on Dec 31, 2024
-
Net Profit
-$95.5 M (USD)49.45as on Dec 31, 2024
-
EBITDA
-$215.24 M (USD)-4.65as on Dec 31, 2024
-
Total Equity Funding
$190 M (USD)
in 2 rounds
-
Latest Funding Round
$130 M (USD), Series B
Feb 01, 2021
-
Investors
T. Rowe Price
& 11 more
-
Employee Count
181
as on Dec 31, 2024
- Investments & Acquisitions
-
Acquired by
Servier
(Mar 06, 2026)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Day One
Day One is a publicly listed company on the NASDAQ with ticker symbol DAWN in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Day One
Day One offers a comprehensive portfolio of products and services, including OJEMDA™ (tovorafenib) and Tovorafenib DAY301.
A targeted therapy developed for cancer treatment purposes.
A drug candidate explored for oncology treatment solutions.
People of Day One
Unlock access to complete
Unlock access to complete
Funding Insights of Day One
Day One has successfully raised a total of $190M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $130 million completed in February 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Day One
Day One has secured backing from 12 investors, including institutional and venture fund investors. Prominent investors backing the company include T. Rowe Price, Franklin Templeton and Janus Henderson Investors.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Biotech startups are funded by this venture capital firm.
|
Locked | Locked | Locked | |
|
US private equity investments are managed by BVF Partners.
|
Locked | Locked | Locked | |
|
Health-tech companies are targeted for venture capital investments.
|
Locked | Locked | Locked |
Investor details for Day One
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Day One
Day One has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Mersana.
Investment portfolio details for Day One
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Antibody-drug conjugates for cancer treatment are developed by Mersana.
|
Locked | Locked | 2001 | Locked |
Complete acquisition details for Day One
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Day One
Detailed financials for Day One
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Day One Comparisons
Peer comparison for Day One
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Day One
Detailed competitors of Day One
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Day One
Complete news archive for Day One
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Day One
Day One was founded in 2018 and raised its 1st funding round 2 years after it was founded.
Day One is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Day One is a funded company, having raised a total of $190M across 2 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Day One is 181.
Annual revenue of Day One is $131.16M as on Dec 31, 2024.
Day One Biopharmaceuticals, Inc. is engaged in the development of targeted therapies for cancer treatment, catering to both children and adults. The company operates within the biotechnology sector, emphasizing innovative drug development for oncology. Solutions such as OJEMDA (tovorafenib) are provided to address urgent medical needs. A search development strategy is employed to identify and advance the right programs for patients. The focus is maintained on disrupting traditional drug development to deliver better medicines faster.
Day One offers OJEMDA™ (tovorafenib) and Tovorafenib DAY301.
Yes, Day One is publicly traded on NASDAQ under the ticker symbol DAWN.
Day One has made 1 acquisition, including Mersana.
Day One has 12 investors. Key investors include T. Rowe Price, Franklin Templeton, Janus Henderson Investors, RA Capital, and Servier.
The ticker symbol of Day One is DAWN on NASDAQ.